Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

Jerry, sometimes I almost agree with you. Our hospital doesn't even carry daptomycin and vancomycin is used regularly. As others have posted, vancomycin is a nasty drug, dosing is somewhat complicated, and maintaining therapeutic levels is critical. I've taken the view that daptomycin is really the 'gold standard' for ABSSSI while vancomycin is the low-cost practical 'drug of choice.' I believe there are studies that show that daptomycin is actually more cost-effective than Vancomycin for bacteremia but I haven't seen any studies for ABSSSI.

It makes sense to hurdle the lowest bar to gain drug approval. For eventual marketing, most docs would be impressed with superiority to vancomycin while referencing daptomycin. However, a lot of hospitals are using a heck of a lot of daptomycin at premium pricing and those facilities aren't going to make the switch unless the argument for Brilacidin is direct and compelling.